Rapid clinical evolution for COVID-19 translates into early hospital admission and unfavourable outcome: A preliminary report
Background: A wide range of mortality rates has been reported in COVID-19 patients on the intensive care unit. We wanted to describe the clinical course and determine the mortality rate in our institution’s intensive care units.
Methods: To this end, we performed a retrospective cohort study of 50 COVID-19 patients admitted to the ICU at a large German tertiary university hospital. Clinical features are reported with a focus on ICU interventions, such as mechanical ventilation, prone positioning and extracorporeal organ support. Outcome is presented using a 7-point ordinal scale on day 28 and 60 following ICU admission.
Results: The median age was 64 years, 78% were male. LDH and D-Dimers were elevated, and patients were low on Vitamin D. ARDS incidence was 75%, and 43/50 patients needed invasive ventilation. 22/50 patients intermittently needed prone positioning, and 7/50 required ECMO. The interval from onset of the first symptoms to admission to the hospital and to the ICU was shorter in non-survivors than in survivors. By day 60 after ICU admission, 52% of the patients had been discharged. 60-day mortality rate was 32%; 37% for ventilated patients, and 42% for those requiring both: ventilation and renal replacement therapy.
Conclusions: Early deterioration might be seen as a warning signal for unfavourable outcome. Lung-protective ventilation including prone positioning remain the mainstay of the treatment.
. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020;323:2052-9. DOI: https://doi.org/10.1001/jama.2020.6775
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20. DOI: https://doi.org/10.1056/NEJMoa2002032
Dreher M, Kersten A, Bickenbach J, Balfanz P, Hartmann B, Cornelissen C, et al. The characteristics of 50 hospitalized COVID-19 patients with and without ARDS. Dtsch Arztebl Int 2020;117:271-8. DOI: https://doi.org/10.3238/arztebl.2020.0271
Yang X, Yu Y, Xu J, Shu H, Xia Ja, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475-81. DOI: https://doi.org/10.1016/S2213-2600(20)30079-5
Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle Region — Case series. N Engl J Med 2020;382:2012-22. DOI: https://doi.org/10.1056/NEJMoa2004500
Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 2020;323:1612-4. DOI: https://doi.org/10.1001/jama.2020.4326
Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016;315:788-800. DOI: https://doi.org/10.1001/jama.2016.0291
Auld SC, Caridi-Scheible M, Blum JM, Robichaux C, Kraft C, Jacob JT, et al. ICU and ventilator mortality among critically ill adults with Coronavirus Disease 2019. Crit Care Med 2020;48:e799-809. DOI: https://doi.org/10.1097/CCM.0000000000004457
Bouch DC, Thompson JP. Severity scoring systems in the critically ill. Continuing Education in Anaesthesia Critical Care & Pain 2008;8:181-5. DOI: https://doi.org/10.1093/bjaceaccp/mkn033
Vincent J-L, Moreno R. Clinical review: Scoring systems in the critically ill. Crit Care 2010;14:207. DOI: https://doi.org/10.1186/cc8204
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506. DOI: https://doi.org/10.1016/S0140-6736(20)30183-5
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus–infected pneumonia in Wuhan, China. JAMA 2020;323:1061-9. DOI: https://doi.org/10.1001/jama.2020.1585
Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial. JAMA 2020;324:1048-57. DOI: https://doi.org/10.1001/jama.2020.16349
Rothe K, Feihl S, Schneider J, Wallnöfer F, Wurst M, Lukas M, et al. Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship. Eur J Clin Microbiol Infect Dis 2020. DOI: https://doi.org/10.1007/s10096-020-04063-8
Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X, et al. Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: A longitudinal study. Radiology 2020;296:e55-64. DOI: https://doi.org/10.1148/radiol.2020200843
Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing in Coronavirus Disease 2019 (COVID-19) in China: A report of 1014 cases. Radiology 2020;296:e32-40. DOI: https://doi.org/10.1148/radiol.2020200642
ARDS Definition Task Force, Ranieri MR, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: The Berlin definition. JAMA 2012;307:2526-33.
Zádori N, Váncsa S, Farkas N, Hegyi P, Erőss B, Szakó L, et al. The negative impact of comorbidities on the disease course of COVID-19. Intensive Care Med 2020;46:1784-6. DOI: https://doi.org/10.1007/s00134-020-06161-9
Chen L, Yu J, He W, Chen L, Yuan G, Dong F, et al. Risk factors for death in 1859 subjects with COVID-19. Leukemia 2020;34:2173-83. DOI: https://doi.org/10.1038/s41375-020-0911-0
Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med 2020;8:853-62. DOI: https://doi.org/10.1016/S2213-2600(20)30316-7
Tzotzos SJ, Fischer B, Fischer H, Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit Care 2020;24:516. DOI: https://doi.org/10.1186/s13054-020-03240-7
Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 does not lead to a "typical" acute respiratory distress syndrome. Am J Respir Crit Care Med 2020;201:1299-300. DOI: https://doi.org/10.1164/rccm.202003-0817LE
Bos LDJ. COVID-19–related acute respiratory distress syndrome: Not so atypical. Am J Respir Crit Care Med 2020;202:622-4. DOI: https://doi.org/10.1164/rccm.202004-1423LE
Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care 2020;24:154. DOI: https://doi.org/10.1186/s13054-020-02880-z
Barbaro RP, MacLaren G, Boonstra PS, Iwashyna TJ, Slutsky AS, Fan E, et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet 2020;396:1071-8. DOI: https://doi.org/10.1016/S0140-6736(20)32008-0
RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL. Dexamethasone in hospitalized patients with Covid-19 — Preliminary report. N Engl J Med 2021;384:693-704. DOI: https://doi.org/10.1056/NEJMoa2021436
Pan H, Peto R, Karim QA, Alejandria M, Henao-Restrepo AM, García CH, et al. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. medRxiv 2020:2020.10.15.20209817.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lance. 2020;395:1569-78. DOI: https://doi.org/10.1016/S0140-6736(20)31022-9
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 — Final report. N Engl J Med 2020;383:1813-26. DOI: https://doi.org/10.1056/NEJMoa2007764
Laird E, Rhodes J, Kenny RA. Vitamin D and inflammation: Potential implications for severity of Covid-19. Ir Med J 2020;113:81.
Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin Exp Res 2020;32:1195-8. DOI: https://doi.org/10.1007/s40520-020-01570-8
Kaufman HW, Niles JK, Kroll MH, Bi C, Holick MF. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. PLoS One 2020;15:e0239252. DOI: https://doi.org/10.1371/journal.pone.0239252
Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, Alcalá Díaz JF, López Miranda J, Bouillon R, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. J Steroid Biochem Mol Biol 2020;203:105751. DOI: https://doi.org/10.1016/j.jsbmb.2020.105751
- Abstract views: 79
- PDF: 31
- Supplementary: 3
Copyright (c) 2021 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.